Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...

(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor ...

Aromatase inhibitors, such as anastrozole, have been used off-label to increase height in children with short stature; however, few studies have investigated the use of aromatase inhibitors in ...

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

Dr Toni Hazell outlines the key updates to NICE menopause guidance and advises on how to interpret and implement the ...